Micro-elimination. A path to global elimination of hepatitis C. Prof Jeffrey V. Lazarus
|
|
- Harry Matthews
- 5 years ago
- Views:
Transcription
1 Micro-elimination A path to global elimination of hepatitis C Prof Jeffrey V. Lazarus [Jeffrey.Lazarus@isglobal.org] Associate Researcher/Assoc Professor, ISGlobal, Hospital Clínic, University of Barcelona CHIP, Rigshospitalet, University of Copenhagen, WHO Collaborating Centre on HIV and Viral Hepatitis 1 - Hep-Micro-elim 2017
2 Meeting two types of challenges Biomedical Public health Hepatitis C DAA breakthrough: 2013 Access Coverage ELIMINATION 2 - Hep-Micro-elim 2017
3 Elimination is Daunting Cost of implementing the WHO global health sector strategy on viral hepatitis, Challenging Costly Complex 3 - Hep-Micro-elim 2017
4 Micro-Elimination A New Concept? When eating an elephant take one bite at a time - Creighton Abrams (US General) 4 - Hep-Micro-elim 2017
5 Micro-Elimination in Other Infectious Disease Polio Countries Regions HIV PMTCT Fast-track cities 5 - Hep-Micro-elim 2017
6 HCV (micro-) elimination in certain populations is feasible in the short-tomedium term Decompensated cirrhotics Veterans Patients with haemophilia Transplant patients PWID, prisoners HIV/HCV co-infected 6 - Hep-Micro-elim 2017 Source: Lazarus JV, Wiktor SZ, Colombo M, Thursz M. Micro-elimination a path to global elimination of hepatitis C. Journal of Hepatology, July 2017.
7 Eliminate late presentation Source: Mauss et al. BMC Med, Hep-Micro-elim 2017
8 Haemophilia Source: Irish Examiner, 22 Dec Source: Department of Health, 22 Dec Hep-Micro-elim 2017
9 Advantages of Micro-Elimination Realistic targets/goals Pragmatic Time to achievement is shorter Tailored strategy Cost can be predicted Prevention of re-infection in a target group Micro-elimination projects may generate a template in a small geographically-defined population which may then be used to model services for larger intervention programmes Micro-elimination could address low-hanging fruit, which would encourage further public health efforts 9 - Hep-Micro-elim 2017
10 Every country needs a bespoke strategy to reduce disease burden and eliminate HCV Public health threat 2. Treat high incidence Prevent new infections, contain the epidemic 3. Non-PWID screening and treatment Elimination Burden of disease threat 1. Treat F3/F4 patients Prevent mortality and morbidity High incidence population Slow progression population Advanced population Risk of onward transmission Risk of mortality and morbidity F0 F1 F2 F3 F4 One approach does not fit all Context matters! 10 - Hep-Micro-elim 2017 Source: Grebely et al. Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements. CID 2013.
11 WHO Global Health Sector Strategy on Viral Hepatitis May 2016: The first of its kind, WHO publishes a global strategy aiming for elimination of viral hepatitis as a public health threat by 2030 Source: WHO Global Health Sector Strategy on viral hepatitis. Available at: (Accessed August 2016) 11 - Hep-Micro-elim 2017
12 Global Health Sector Strategy HCV targets at a glance Incidence targets 30% reduction in new HCV infections by % reduction in new HCV infections by 2030 Mortality targets 10% reduction in mortality by % reduction in mortality by 2030 Harm reduction Increase in sterile needle and syringes provided per PWID/year from 20 in 2015 to: 200 by by 2030 Testing targets 90% of people aware of HCV infection by 2030 Treatment targets 80% of people treated by 2030 Source: WHO GHSS. (Accessed August 2016) Hep-Micro-elim 2017
13 The global cascade of care for chronic HCV infection in 2015 Adapted by Macmillan Publishers Ltd, part of Springer Nature with permission, from Global Hepatitis Report, 2017, World Health Organization, page 30, figure 8, Source: Lazarus JV. et al. Many European countries flying blind in their efforts to eliminate viral hepatitis. Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro Hep-Micro-elim 2017
14 The continuum of viral hepatitis services and the retention cascade Source: WHO Global Hepatitis Report, Available at (accessed May 2017) Hep-Micro-elim 2017
15 People-centred health systems See: Hep-Micro-elim 2017
16 A people-centred health system for hepatitis elimination Effective surveillance/monitoring of loss to follow up? National strategy/plan incl stakeholder input eg patients, risk groups, clinicians? Strategies for engaging eg key affected populations? Workforce needed to achieve elimination? Capacity to monitor disease progression? Budget for provision of testing & treatment? 16 - Hep-Micro-elim 2017
17 Table 1. Target populations for microelimination of hepatitis C in X Sub-group Estimated or reported # of chronically HCVinfected people Children (under age 15) 35 Coinfected with HIV 423 Generational cohorts of high No data prevalence (born ) Haemodialysis patients 67 Haemophilia patients Men who have sex with men No national data; 19 at one site No data Migrants from high-prevalence 12,607 countries Patients with advanced liver 56,340 (0.57%) including (19.4%) F3 and disease (9.2%) F4 People who inject drugs 5,743 Prisoners 1, Hep-Micro-elim 2017 Transplant patients No national data; 9 at one site Source: Lazarus et al. In press 2018
18 Some countries may achieve the WHO targets by or even before 2030 Iceland Georgia Australia National plan to treat all HCV patients according to Icelandic guidelines over 3 years Prioritisation of active PWID and patients with moderate-to-severe fibrosis Jan to Dec 2016, 1/3 of the HCV population were treated Georgia HCV Elimination Program Prioritisation of patients with advanced liver disease April 2015 to April 2016, 8448 people treated, a 400% increase in the number patients treated over the previous 4 years Public health policy 2016, 15% (33,560 patients) of the HCV population were treated No disease stage restrictions No drug or alcohol use restrictions GPs can prescribe Sources: Gottfredsson F, et al. HIV and Hepatitis Nordic Conference 2016; Abstract #O5; Gvinjilia L, et al. MMWR 2016;65:1132 5; Monitoring hepatitis C treatment uptake in Australia. Issue #5, September Available at: (accessed Aug 2017) 18 - Hep-Micro-elim 2017
19 International Viral Hepatitis Elimination Meeting 2018 Est Nov 2017 Price BREAKING NEWS--? is the first country to eliminate hepatitis C among? 19 - Hep-Micro-elim 2017
20 Some questions to discuss What is micro-elimination and why is it important? What examples of successful micro-elimination exist? Why focus on a micro-elimination endeavor rather than a larger elimination goal? How does micro-elimination inform a larger elimination project? How do you prioritize a micro-elimination project within a larger elimination goal? For example, do you eliminate HCV in a subset of a population that contributes to incidence increases? Or do you focus on a subset of a population who is at greatest risk of mortality or morbidity from HCV? 20 - Hep-Micro-elim 2017
21 Acknowledgements The EASL International Liver Foundation and in particular Massimo Colombo, Mark Thursz, Stefan Wiktor Kelly Safreed-Harmon, ISGlobal, Hospital Clínic Contact: 21 - Hep-Micro-elim 2017
Health systems requirements for viral hepatitis elimination: Are we 'Flying Blind' in our efforts?
Health systems requirements for viral hepatitis elimination: Are we 'Flying Blind' in our efforts? Prof Jeffrey V. Lazarus [Jeffrey.Lazarus@isglobal.org CHIP, Rigshospitalet, University of Copenhagen,
More informationStrengthening efforts to eliminate hepatitis C: An overview of the latest in research and implications for frontline workers
Strengthening efforts to eliminate hepatitis C: An overview of the latest in research and implications for frontline workers Rivka Kushner, knowledge specialist, Hepatitis C, CATIE Jason Altenberg, director
More informationGlobal, regional and national strategic planning for viral hepatitis prevention and control
Global, regional and national strategic planning for viral hepatitis prevention and control Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Baltic Meeting 19 20 November 2015 Riga, Latvia Presentation
More informationHCV: how do we reach elimination from a clinicians perspective. A/Professor Gail Matthews
HCV: how do we reach elimination from a clinicians perspective A/Professor Gail Matthews WHO global hepatitis elimination goals by 2030 Elimination a reduction in HCV incidence and HCVrelated mortality
More informationHepatitis C Strategy. About us. What is hepatitis C?
Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with
More informationIs Elimination of Hepatitis C Possible?
Is Elimination of Hepatitis C Possible? JORGE MERA, MD CHEROKEE NATION DISCLOSURE INFORMATION The presenter has nothing to disclose. Outline Scope of the problem Definitions Is elimination of HCV needed?
More informationThe Global Movement to Eliminate Viral Hepatitis. John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA
The Global Movement to Eliminate Viral Hepatitis John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA Infection and Disease Control, Elimination and Eradication Control Below acceptable
More informationHow to prioritise HCV treatment
How to prioritise HCV treatment From the perspective of the medical community Margaret Hellard Declarations NHMRC fellowship Burnet receives infrastructure support from the Victorian Government Gilead
More informationObstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis
Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and
More informationImproving efficiency in health. Hepatitis C virus session
Improving efficiency in health Hepatitis C virus session Aims of this session Optima is a tool to assist in reducing the burden of diseases by optimizing resource allocation. This session will discuss:
More informationMonitoring the Implementation of Hepatitis B and C Policy Recommendations in Europe
The 2016 ELPA Report Monitoring the Implementation of Hepatitis B and C Policy Recommendations in Europe March 22, 2017 - European Parliament Livia Alimena ELPA Public Affairs Director pad@elpa-info.org
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationGlobal strategy on viral hepatitis and regional action plan: monitoring framework and 10 core indicators
Global strategy on viral hepatitis and regional action plan: monitoring framework and 10 core indicators Antons Mozalevskis WHO Regional Office for Europe EMCDDA DRID National Expert Meeting Lisbon, 6
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationHepatitis C Elimination: Australia s progress
Hepatitis C Elimination: Australia s progress Margaret Hellard Burnet Institute, Melbourne Disclosures I receive fellowship support from the National Health and Medical Research Council (Australia). The
More informationGlobal health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )
Regional Committee for Europe 65th session EUR/RC65/Inf.Doc./3 Vilnius, Lithuania, 14 17 September 2015 2 September 2015 150680 Provisional agenda item 3 ORIGINAL: ENGLISH Global health sector strategies
More informationModels of HCV screening & treatment: An evidence-based international perspective
Scottish University of the Year 2017 Models of HCV screening & treatment: An evidence-based international perspective Prof John F Dillon Page 1 Declaration of Financial Interests or Relationships Speaker
More informationHIV and HCV coinfection - Barriers in Central and Eastern Europe
HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical
More informationStrategies to Address HCV
Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The
More informationBruce Kreter, PharmD Senior Director, Global HCV Medical Affairs Gilead Sciences, Inc.
CDC Foundation & Viral Hepatitis Action Coalition: Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States Bruce Kreter, PharmD Senior Director, Global HCV
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More informationGraham Cooke. Imperial College & Imperial College NHS Trust. NIHR Research Professor. BHIVA meeting October 2018
Graham Cooke Imperial College & Imperial College NHS Trust NIHR Research Professor BHIVA meeting October 2018 @grahamscooke The Big Picture Scaling up the global response The role of microelimination The
More informationElimination of hepatitis C. Jon Florholmen HCV NORD Research Group Gastroenterology and Nutrition The Norwegian Artic University, Tromsø NORWAY
Elimination of hepatitis C Jon Florholmen HCV NORD Research Group Gastroenterology and Nutrition The Norwegian Artic University, Tromsø NORWAY Elimination of hepatitis C History Definition and World Health
More informationToronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally A call for coordinated action Disclaimer Toronto declaration is not aiming to reinvent the wheel or interfere
More informationOvercoming barriers to access to hepatitis C treatment in a rapidly changing landscape
Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape HIV/AIDS Department and Global Hepatitis Programme Dr. Stefan Wiktor Outline Global Hepatitis Strategy New HCV treatment
More informationMANDERA COUNTY REPORT ON THE HIV IMPLEMENTING PARTNERS ONLINE REPORTING SYSTEM (HIPORS) FOR THE FINANCIAL YEAR 2016/2017 FEBRUARY 2018.
MANDERA COUNTY REPORT ON THE HIV IMPLEMENTING PARTNERS ONLINE REPORTING SYSTEM (HIPORS) FOR THE FINANCIAL YEAR 2016/2017 FEBRUARY 2018 Page 1 of 5 HIV IMPLEMENTING PARTNERS ONLINE REPORTING SYSTEM (HIPORS)
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationItem 4. Sexual Health and Blood Borne Virus Strategy Strategy for Sexual Health and Blood Borne Viruses. Background
Item 4 Strategy for Sexual Health and Blood Borne Viruses Background 1. In August 2011 the Scottish Government launched a joint Sexual Health and Blood Borne Virus Framework. This brought four policy areas
More informationCall to Action. Global and Regional Hepatitis Action Plans: Opportunities and considerations for China
Call to Action Global and Regional Hepatitis Action Plans: Opportunities and considerations for China Po-Lin Chan, Senior Advisor Hepatitis/HIV/STI Lan Zhang, Senior Medical Officer Hepatitis/HIV/STI WHO
More informationBUSIA COUNTY REPORT ON THE HIV IMPLEMENTING PARTNERS ONLINE REPORTING SYSTEM (HIPORS) FOR THE FINANCIAL YEAR 2016/2017 FEBRUARY 2018.
BUSIA COUNTY REPORT ON THE HIV IMPLEMENTING PARTNERS ONLINE REPORTING SYSTEM (HIPORS) FOR THE FINANCIAL YEAR 2016/2017 FEBRUARY 2018 Page 1 of 5 HIV IMPLEMENTING PARTNERS ONLINE REPORTING SYSTEM (HIPORS)
More informationEliminating Viral Hepatitis in Australia: Where are we in 2017?
This document was prepared by Hepatitis Australia in consultation with a variety of stakeholders working in the areas of hepatitis B and hepatitis C in Australia. This included people involved in primary
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationSection 7: Providing HCV testing and treatment to people who inject drugs
Section 7: Providing HCV testing and treatment to people who inject drugs Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective
More informationHepatitis C. Request a Test. Benefits of testing in AOD services to improve treatment uptake
Hepatitis C Request a Test Benefits of testing in AOD services to improve treatment uptake Jenny Bourke Clinical Nurse Specialist Hepatitis C Community Clinic Christchurch About Hepatitis C Hepatitis is
More informationA SYSTEMATIC REVIEW OF HEPATITIS B AND C TESTING IN THE COUNTRIES OF THE WHO EUROPEAN REGION
A SYSTEMATIC REVIEW OF HEPATITIS B AND C TESTING IN THE COUNTRIES OF THE WHO EUROPEAN REGION Jeffrey V. Lazarus* 1, Ida Sperle1, Jürgen K. Rockstroh2, Alexander Spina3, Lucas Wiessing4 1CHIP, Rigshospitalet,
More informationGlobal reporting system for hepatitis (GRSH) project description
Global reporting system for hepatitis (GRSH) project description Contents 1. Background... 2 2. Target audience for this document... 2 3. Data to be reported through the Global Reporting System for Hepatitis...
More informationUnderstanding your epidemic: WHO tools for hepatitis surveillance
. Understanding your epidemic: WHO tools for hepatitis surveillance Dr Antons Mozalevskis / WHO Regional Office for Europe Dr Yvan Hutin / Global Hepatitis Programme, WHO Headquarters 25 October 2018,
More informationPublic Health Response to HCV in Oregon: Need for Screening and Treatment. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention
Public Health Response to HCV in Oregon: Need for Screening and Treatment Ann Thomas, MD, MPH Acute and Communicable Disease Prevention November 29, 2018 Outline I. Epidemiology of HCV in OR acute HCV,
More informationPrevention and control of hepatitis B and C in the European Region of WHO
Prevention and control of hepatitis B and C in the European Region of WHO Viral Hepatitis Prevention Board Dr Nedret Emiroglu WHO Regional Office for Europe Burden of viral hepatitis in the European Region
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationU.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs
U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs Michelle Van Handel, MPH Health Scientist National Center for HIV/AIDS, Viral Hepatitis, STDs and
More informationThe National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015
The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015 December 21, 2015 2 December 21, 2015 3 Can we eliminate hepatitis C? Treatments December 21, 2015 4 We Have the Roadmap
More informationNational Viral Hepatitis Action Plan Priority Populations Approach
National Viral Hepatitis Action Plan Priority Populations Approach November 29, 2017 Corinna Dan, RN, MPH Office of HIV/AIDS and Infectious Disease Policy Office of the Assistant Secretary for Health Department
More informationNational Hepatitis C Elimination Program of Georgia
European Roundtable on Hepatitis Cure & Eradication 2015 9-10 September 2015, Frankfurt, Germany National Hepatitis C Elimination Program of Georgia Tengiz Tsertsvadze MD, PhD Director General Infectious
More informationRECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS
RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS The International Network on Hepatitis in Substance users (INHSU) Olav Dalgard Oslo Grebely J et al Int J
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationHepatitis C in Massachusetts Epidemiology and Public Health Response
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Epidemiology and Public Health Response Shauna Onofrey, MPH, Viral Hepatitis
More informationHIV, HBV and HCV testing policy experiences and lessons learned.
HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence
More informationInstitute of Quality Leadership AMGA
Institute of Quality Leadership AMGA Ajay Sahajpal, MD Director Abdominal Transplant and Hepatobiliary Program Bradley Kruger, VP Operations ASLMC Laura Spurr, Director Clinical Transformation and Operations
More informationViral Hepatitis Burden and Policy Directions in the European Region of WHO
Viral Hepatitis Burden and Policy Directions in the European Region of WHO Dr Nedret Emiroglu WHO Regional Office for Europe Brussels 14-15 October 2010 Global Burden of Chronic Viral Hepatitis 2.7% all
More informationSuccessful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection
Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection Liz Highleyman Produced in collaboration with hivandhepatitis.com Published: 28 October 2015 Jump to Trends
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I 2011 Rationale for including this activity in the proposal The World Health Organization (WHO), the Joint United
More informationFelice Nava, MD, PhD Felice A. Nava, MD PhD
Felice Nava, MD, PhD Felice A. Nava, MD PhD Direttore U.O. Sanità Penitenziaria Azienda ULSS 6 Euganea Padova Direttore Comitato Scientifico Nazionale FeDerSerD HCV 0? Dall Eradicazione del virus alla
More informationAccess to HCV treatment in Egypt
Access to HCV treatment in Egypt Prof. Gamal Esmat Prof. Hepatology &Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Global genotype distribution
More informationPlacing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat
Placing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat John W. Ward, M.D Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD &
More informationHepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatitis-c-virus-hcvcurrent-screening-guidelines-treatment-approaches/9514/
More informationPerspective.
Perspective Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization s global health sector strategy core indicators and
More informationNational Hepatitis plan. Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology
National Hepatitis plan Dr JP Mulkay Clinic of Hepatology Department of Hepato Gastro entrology National hepatitis Plan Hepatitis B: plan non existent. People s migration from endemic countries. Reimbursement
More informationHCV epidemiology: Access to treatment and care on a global level Margaret Hellard
HCV epidemiology: Access to treatment and care on a global level Margaret Hellard Burnet Institute, Melbourne Disclosures I receive fellowship support from the National Health and Medical Research Council
More informationModeling what is required to prevent HIV and HCV among people who inject drugs in the U.S.
Modeling what is required to prevent HIV and HCV among people who inject drugs in the U.S. Natasha K Martin, DPhil Associate Professor Division of Infectious Diseases and Global Health, University of California
More informationSIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat
SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic
More informationMichael Levy Australian National University
Treatment is Prevention Do not under-estimate the importance of prevention as the key to treatment Michael Levy Australian National University The Burden World Health Assembly (2014) 1.4 million deaths
More informationPreparedness for candidate HCV vaccine trials in people who inject. C Vaccine Initiative*
Preparedness for candidate HCV vaccine trials in people who inject drugs: Challenges and opportunities Li M h b h lf f th UNSW H titi Lisa Maher, on behalf of the UNSW Hepatitis C Vaccine Initiative* Background
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More information>Hepatitis NSW will continue to
Continued Equal Treatment Access to hepatitis C medicines KURT SAYS Everyone with viral hepatitis deserves equal access to treatment. Thankfully Australians can access hepatitis C treatment before they
More informationUpdate on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018
Update on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018 Overview Background to injecting drug use Overview of harm reduction Data on Hepatitis Summary of services provided by
More informationPREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS
PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS Holly Hagan, PhD Professor Co-Director, Center for Drug Use and HIV Research Principal Investigator, HCV Synthesis Project New York University HCV prevalence
More informationImplementation of testing (and other interventions along the Continuum of Care)
Implementation of testing (and other interventions along the Continuum of Care) Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Centers for Disease Control
More informationSetting the Stage Key Challenges in Elimination
Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,
More informationIntegrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson
Integrating hepatitis C treatment in a regional setting The Cairns Experience DANA 2018 Morag Goodinson I would like to acknowledge the Traditional Owners of the land, and pay respect to Elders past, present
More informationSurveillance and Treatment of Prisoners with hepatitis C (SToP-C) Professor Andrew Lloyd Wednesday 7 th October 2015
Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Professor Andrew Lloyd Wednesday 7 th October 2015 Australian prison population 30,775 5% 34 92% Total population Increase from 2012 Median
More informationHepatitis C The NHS Model. Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL
Hepatitis C The NHS Model Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL The NHS Approach Background The strategy Tactics The NHS Approach Background The strategy Tactics NHSE
More informationLa dernière frontière : simplification et intégration des soins
Jean-Michel Delile CEID, Bordeaux Vice-président de la Fédération Addiction jm.delile@ceid-addiction.com ATHS Biarritz, 18/10/2017 Atelier «Simplifier pour éliminer l hépatite C» La dernière frontière
More informationThe forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre
The forgotten group: a new HIV outbreak amongst people who inject drugs Patricia Anderson Lead CNS BBV Brownlee Centre No conflicts to declare Potted History 1981 Modern wave of drug misuse Glasgow soared
More informationELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD
ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD 17 May 2018 Bucharest, Romania Organisers Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe
More informationEpidemiology and Priority Actions for Curing HCV and Treating Chronic HBV
Epidemiology and Priority Actions for Curing HCV and Treating Chronic HBV Dr. Marc Bulterys Monday 27 th March 2017 MPP meeting at InterCon Hotel Overview of Presentation Hepatitis global elimination strategy
More informationHow France is eliminating HCV and the role of screening strategies
HCV Elimination Mini Policy Summit «Eliminating HCV in Romania» European Parliament, 27 September 2017 How France is eliminating HCV and the role of screening strategies Sylvie Deuffic-Burban, Inserm,
More informationRegional Action Plan for Viral Hepatitis in the Western Pacific
WORLD HEALTH ORGANIZATION REGIONAL OFFICE OF THE WESTERN PACIFIC Regional Action Plan for Viral Hepatitis in the Western Pacific Draft for virtual consultation A regional priority action plan for awareness,
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationAfter the Cure: Looking Ahead in HCV Management. Nancy Reau, MD
After the Cure: Looking Ahead in HCV Management Nancy Reau, MD Objectives 1. Discuss current recommendations in HCV screening, performance and limitations 2. Discuss linkage to care, hurdles and strategies
More informationHCV ACTION EAST OF ENGLAND HEPATITIS C GOOD PRACTICE ROADSHOW, 9TH MAY 2017 SUMMARY REPORT
HCV ACTION EAST OF ENGLAND HEPATITIS C GOOD PRACTICE ROADSHOW, 9TH MAY 2017 SUMMARY REPORT Introduction With hepatitis C representing a significant public health concern in the Cambridge and East of England
More informationPromoting hepatitis B vaccination
Promoting hepatitis B vaccination Introduction Hepatitis B is a serious blood borne infection that can exacerbate hepatitis C infection, can cause serious liver damage and sometimes results in death. Hepatitis
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationModelling the Impact of Interventions Targeting High- Risk Populations on the HCV Epidemic in Resource- Limited Settings Pakistan as a Case Study
1 Modelling the Impact of Interventions Targeting High- Risk Populations on the HCV Epidemic in Resource- Limited Settings Pakistan as a Case Study Aaron G. Lim, Matthew Hickman, Peter Vickerman Population
More informationHepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious
More informationHepatitis C Elimination Program Georgia
Hepatitis C Elimination Program Georgia Maia Butsashvili, MD, MS, PhD Health Research Union (HRU)/Clinic NEOLAB National HCV Committee International School of Public Health High prevalence of HCV in Georgia
More informationAN OVERVIEW OF POLICIES FOR PREVENTION, CARE AND TREATMENT OF HEPATITIS B AND C (part B)
AN OVERVIEW OF POLICIES FOR PREVENTION, CARE AND TREATMENT OF HEPATITIS B AND C (part B) GEORGE PAPATHEODORIDIS, MD ASSOCIATE PROFESSOR IN MEDICINE AND GASTROENTEROLOGY, ATHENS UNIVERSITY MEDICAL SCHOOL
More informationHCV Elimination in France
HCV Elimination in France Stanislas Pol, MD, PhD PHC 14 January 2017 Liver Department, Hôpital Cochin Inserm U-1223, Institut Pasteur Université Paris Descartes, Paris, France stanislas.pol@aphp.fr Disclosures
More informationTreatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017
Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017 Conflicts of interest Receive
More informationModels of care for management of HCV among PWID. Philip Bruggmann Switzerland
Models of care for management of HCV among PWID Philip Bruggmann Switzerland Disclosures Speaker and advisory board fees from Merck, Abbvie, Gilead, Janssen and BMS Financial support for projects of Arud
More informationThe time has come to eliminate hepatitis C in Canada Executive Summary
1 The time has come to eliminate hepatitis C in Canada Executive Summary CTAC is Canada s non-governmental organization led by and for people living with HIV and HIV/HCV co-infection, focusing on access
More informationAngelos Hatzakis. 10th Paris Hepatology Conference
Angelos Hatzakis Professor of Epidemiology and Preventive Medicine Faculty of Medicine National and Kapodistrian University of Athens Co-Chair, Hepatitis B and C Public Policy Association 10th Paris Hepatology
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 5
National Clinical Guidelines for the treatment of HCV in adults Version 5 June 2018 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN co-ordinators
More informationHIV/AIDS Joint Action HA-REACT
HIV/AIDS Joint Action HA-REACT Matthias Schuppe Policy Officer Health Threats Unit DG Health and Food Safety European Commission Policy Framework on HIV/AIDS in EU and neighbouring countries Commission
More informationAction plan for the health sector response to viral hepatitis in the WHO European Region
Action plan for the health sector response to viral hepatitis in the WHO European Region Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Albania Country Meeting: Tirana, 27-28 October 2016 Chronic
More informationWHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections
Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections
More informationEstimating the incidence and prevalence of chronic hepatitis C (HCV) in Ireland
Estimating the incidence and prevalence of chronic hepatitis C (HCV) in Ireland Niamh Murphy & Lelia Thornton Health Protection Surveillance Centre RCPI, Faculty of Public Health Summer Scientific Meeting
More information